VivoSeq
Other

Nivolumab

0

Pipeline Programs↗

19

Active Trials↗

6

Companies Involved↗

Nivolumab is an early-stage landscape with 0 programs across 6 companies. The most active players are Bristol-Myers Squibb, Dragonfly Therapeutics, Tessa Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

71/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalD

Dragonfly Therapeutics

0 programs

PreclinicalT

Tessa Therapeutics

0 programs

PreclinicalTaiho Oncology, Inc. logo

Taiho Oncology, Inc.

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalA

AVEO Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

55

clinical trials

Completed20 · 36%
Recruiting11 · 20%
Active, not recruiting8 · 15%
Unknown status6 · 11%
Terminated6 · 11%
No longer available1 · 2%
Other3 · 5%

Clinical Trials

Trial Activity

55 trials

Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
Recruiting·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT07234487·178 enrolled
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
Recruiting·EErasmus Medical Center·Phase 4·NCT06116461·34 enrolled
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
Recruiting·—·Phase 2·NCT05817903·118 enrolled
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Recruiting·MMayo Clinic·Phase 2·NCT06265285·50 enrolled
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
Recruiting·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT05310643·30 enrolled
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
Recruiting·—·Phase 1·NCT04003649·60 enrolled
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
Recruiting·EErasmus Medical Center·N/A·NCT05652673·80 enrolled
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
Recruiting·SSarcoma Oncology Research Center, LLC·Phase 2·NCT03886311·200 enrolled
Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy
Recruiting·UUniversity of Melbourne·Phase 1/2·NCT05187429·42 enrolled
KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT05254184·12 enrolled
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT03465592·39 enrolled
Fedratinib in Combination With Nivolumab
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05393674·30 enrolled
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
Active, not recruiting·TTessa Therapeutics·Phase 1·NCT05352828·15 enrolled
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Active, not recruiting·—·Phase 2·NCT03333616·100 enrolled
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Active, not recruiting·TToni Choueiri, MD·Phase 2·NCT03203473·85 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)